New vaccine combo aims to stop liver Cancer's comeback
NCT ID NCT06218511
Summary
This early-stage trial is testing a new combination treatment for people with early-stage liver cancer who have already received standard care. The goal is to see if a vaccine plus an immunotherapy drug (durvalumab) is safe and can train the body's immune system to prevent the cancer from coming back. The study will enroll about 10 patients to check for side effects and see if the treatment triggers a strong immune response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Luigi Buonaguro
Naples, Napoli, 80131, Italy
Conditions
Explore the condition pages connected to this study.